Renal protective effect in hypertensive patients: The high doses of angiotensin II receptor blocker (HARB) study
Renal protective effect in hypertensive patients: The high doses of angiotensin II receptor blocker (HARB) study
复制标题
DOI：
10.1291/hypres.30.1187
复制
发表时间：
2007-12-01
影响因子：
5.4
通讯作者：
Ogihara, Toshio
中科院分区：
文献类型：
--
作者：
Ohishi, Mitsuru;Takagi, Takashi;Ogihara, Toshio
血管紧张素受体阻滞剂(ARB)是治疗慢性肾脏疾病推荐的一线抗高血压药物，严格的血压调节对于减少蛋白尿至关重要。Valsartan和Candesartan是日本常用的ARB，最大允许剂量分别为160毫克/天和12毫克/天。根据日本高血压学会高血压治疗指南(JSH 2004)，我们评估了55名接受坎地沙坦治疗的血压控制不佳的高血压患者从最大剂量坎地沙坦转换为最大剂量valsartan后的血压和蛋白尿。治疗前后测量血压、脉率，并测定尿蛋白排泄量。转换与收缩压和舒张压从158/89毫米汞柱下降到150/86毫米汞柱有关(p
Angiotensin receptor blockers (ARBs) are the recommended first-line antihypertensive treatment for managing chronic kidney disease, and strict blood pressure (BP) regulation is crucial for the reduction of proteinuria. Valsartan and candesartan are commonly used ARBs in Japan, with maximum permissible doses of 160 mg/day and 12 mg/day, respectively. We evaluated BP and proteinuria after changeover from the maximum dose of candesartan to the maximum dose of valsartan, in 55 poorly controlled hypertensive patients undergoing candesartan treatment who were unable to achieve optimal BP according to the Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004). We measured BP and pulse rate and assessed urinary protein excretion (UPE) before and after changeover. Changeover was associated with decreases in systolic BP and diastolic BP from 158/89 mmHg to 150/86 mmHg (p